Physician profile
Clive Albert
NPI 1821099987
$10,572.88
in general payments reported to CMS, 2019-2025
38 companies · $2,953 in 2025
The $2,953 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,306 · 2020: $769 · 2021: $627 · 2022: $1,364 · 2023: $895 · 2024: $1,659 · 2025: $2,953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,497 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,496.60 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,637.68 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $772.78 | 2020-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $706.66 | 2022-2025 | Dupixent |
| Pfizer INC. | $562.75 | 2019-2025 | |
| Gilead Sciences, INC. | $465.61 | 2019-2025 | Vemlidy, Livdelzi, Epclusa |
| Allergan, INC. | $439.48 | 2019 | |
| Madrigal Pharmaceuticals | $436.25 | 2025 | Rezdiffra |
| Ardelyx, INC. | $433.53 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $312.88 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $251.81 | 2019-2025 | Entyvio, Gattex |
| Janssen Scientific Affairs, LLC | $228.79 | 2019-2022 | |
| Lilly USA, LLC | $220.20 | 2024-2025 | Omvoh |
| Portola Pharmaceuticals, LLC | $219.24 | 2020 | |
| Medtronic, INC. | $192.85 | 2021-2023 | Endoflip, Bravo |
| Genzyme Corporation | $168.60 | 2022-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $166.68 | 2023-2024 | Sucraid, Sucraid |
| Ipsen Biopharmaceuticals, INC | $143.84 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $141.39 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $103.78 | 2019-2023 | Rebyota |
| E.R. Squibb & Sons, L.L.C. | $101.65 | 2022 | |
| Novo Nordisk INC | $95.82 | 2025 | Wegovy |
| Celgene Corporation | $92.87 | 2022-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $87.23 | 2024 | |
| Merck Sharp & Dohme LLC | $79.98 | 2022-2024 | Dificid |
| Daiichi Sankyo INC. | $76.98 | 2020-2023 | Injectafer |
| Shionogi INC | $69.55 | 2019-2024 | Fetroja |
| Covidien LP | $67.29 | 2020 | |
| Intercept Pharmaceuticals, INC. | $62.87 | 2019-2022 | |
| Braintree Laboratories, INC. | $54.01 | 2024-2025 | Suflave, Sutab |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.20 | 2023 | |
| Evoke Pharma, INC. | $31.73 | 2023 | Gimoti |
| Ucb, INC. | $30.07 | 2019 | |
| Shire North American Group INC | $24.95 | 2019 | |
| Redhill Biopharma INC. | $17.00 | 2020 | |
| Orphalan INC | $16.35 | 2025 | Cuvrior |
| Organon LLC | $13.05 | 2023 | Renflexis |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clive Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.